Rational approach to discover multipotent anti-Alzheimer drugs

Journal of Medicinal Chemistry

Volumn 48, Issue 2, 2005, Pages 360-363

  Rosini, Michela ^a   Andrisano, Vincenza ^a   Bartolini, Manuela ^a   Bolognesi, Maria L ^a   Hrelia, Patrizia ^a   Minarini, Anna ^a   Tarozzi, Andrea ^a   Melchiorre, Carlo ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINESTERASE; AMYLOID BETA PROTEIN; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; LIPOCRINE; REACTIVE OXYGEN METABOLITE; TACRINE; THIOCTIC ACID; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; BIOLOGICAL ACTIVITY; CATALYSIS; CHOLINERGIC TRANSMISSION; CYTOTOXICITY; DRUG ACTIVITY; DRUG INHIBITION; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; OXIDATIVE STRESS; PHARMACOPHORE; PROTEIN AGGREGATION;

ACETYLCHOLINESTERASE; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANTIOXIDANTS; BUTYRYLCHOLINESTERASE; CELL LINE; CHOLINESTERASE INHIBITORS; HUMANS; NEURONS; NOOTROPIC AGENTS; REACTIVE OXYGEN SPECIES; STRUCTURE-ACTIVITY RELATIONSHIP; TACRINE; THIOCTIC ACID;

EID: 12344328416     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm049112h     Document Type: Article

References (22)

1. Hardy, J.; Selkoe, D. J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297, 353-356.
2. Capsoni, S.; Ugolini, G.; Comparini, A.; Ruberti, F.; Berardi, N.; Cattaneo, A. Alzheimer-like neurodegeneration in aged anti-nerve growth factor transgenic mice. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 6826-6831.
3. Bartus, R. T. On neurodegenerative diseases, models, and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Exp. Neurol. 2000, 163, 495-529.
4. Terry, A. V., Jr.; Buccafusco, J. J. The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: recent challenges and their implications for novel drug development. J. Pharmacol. Exp. Ther. 2003, 306, 821-827.
5. Davis, K. L.; Powchik, P. Tacrine. Lancet 1995, 345, 625-630.
6. Bryson, H. M.; Benfield, P. Donepezil. Drugs Aging 1997, 10, 234-239, 240-241 (discussion).
7. Gabelli, C. Rivastigmine: an update on therapeutic efficacy in Alzheimer's disease and other conditions. Curr. Med. Res. Opin. 2003, 19, 69-82.
8. Sramek, J. J.; Frackiewicz, E. J.; Cutler, N. R. Review of the acetylcholinesterase inhibitor galanthamine. Expert Opin. Invest. Drugs 2000, 9, 2393-2402.
9. Packer, L.; Witt, E. H.; Tritschler, H. J. alpha-Lipoic acid as a biological antioxidant. Free Radical Biol. Med. 1995, 19, 227-250.
10. Tirosh, O.; Sen, C. K.; Roy, S.; Kobayashi, M. S.; Packer, L. Neuroprotective effects of alpha-lipoic acid and its positively charged amide analogue. Free Radical Biol. Med. 1999, 26, 1418-1426.
11. Biewenga, G. P.; Haenen, G. R.; Bast, A. The pharmacology of the antioxidant lipoic acid. Gen. Pharmacol. 1997, 29, 315-331.
12. Packer, L. α-Lipoic acid: a metabolic antioxidant which regulates NF-κB signal transduction and protects against oxidative injury. Drug Metab. Rev. 1998, 30, 245-275.
13. Zhang, L.; Xing, G. Q.; Barker, J. L.; Chang, Y.; Maric, D.; Ma, W.; Li, B. S.; Rubinow, D. R. α-Lipoic acid protects rat cortical neurons against cell death induced by amyloid and hydrogen peroxide through the Akt signalling pathway. Neurosci. Lett. 2001, 312, 125-128.
14. Hager, K.; Marahrens, A.; Kenklies, M.; Riederer, P.; Munch, G. α-Lipoic acid as a new treatment option for Azheimer type dementia. Arch. Gerontol. Geriatr. 2001, 32, 275-282.
15. Inestrosa, N. C.; Alvarez, A.; Perez, C. A.; Moreno, R. D.; Vicente, M.; Linker, C.; Casanueva, O. I.; Soto, C.; Garrido, J. Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme. Neuron 1996, 16, 881-891.
16. Bartolini, M.; Bertucci, C.; Cavrini, V.; Andrisano, V. β-Amyloid aggregation induced by human acetylcholinesterase: inhibition studies. Biochem. Pharmacol. 2003, 65, 407-416.
17. Ellman, G. L.; Courtney, K. D.; Andres, V.; Featherstone, R. M. A new rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 1961, 7, 88-95.
18. Recanatini, M.; Cavalli, A.; Belluti, F.; Piazzi, L.; Rampa, A.; Bisi, A.; Gobbi, S.; Valenti, P.; Andrisano, V.; Bartolini, M.; Cavrini, V. SAR of 9-amino-1,2,3,4-tetrahydroacridine-based acetylcholinesterase inhibitors: synthesis, enzyme inhibitory activity, QSAR, and structure-based CoMFA of tacrine analogues. J. Med. Chem. 2000, 43, 2007-2018.
19. Pang, Y. P.; Quiram, P.; Jelacic, T.; Hong, F.; Brimijoin, S. Highly potent, selective, and low cost bis-tetrahydroaminacrine inhibitors of acetylcholinesterase. Steps toward novel drugs for treating Alzheimer's disease. J. Biol. Chem. 1996, 271, 23646-23649.
20. Inestrosa, N. C.; Alvarez, A.; Calderon, F. Acetylcholinesterase is a senile plaque component that promotes assembly of amyloid β-peptide into Alzheimer's filaments. Mol. Psychiatry 1996, 1, 359-361.
21. Piazzi, L.; Rampa, A.; Bisi, A.; Gobbi, S.; Belluti, F.; Cavalli, A.; Bartoiini, M.; Andrisano, V.; Valenti, P.; Recanatini, M. 3-(4-[[Benzyl(methyl) amino]methyl]phenyl)-6,7-dimethoxy-2H-2-chromenome (AP2238) inhibits both acetylcholinesterase and acetylcholinesterase-induced β-amyloid aggregation: a dual function lead for Alzheimer's disease therapy. J. Med. Chem. 2003, 46, 2279-2282.
22. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 1983, 65, 55-63.